Johnson & Johnson has said its single-dose vaccine is 66% effective in preventing Covid-19 globally. The single-shot vaccine, which has been developed by Johnson & Johnson's pharmaceutical arm Janssen, is 66% effective overall at preventing moderate to severe Covid-19 28 days after vaccination.
It said its vaccine was 72% effective in preventing Covid-19 in the United States but a lower rate of 66% was observed globally in the large trial conducted across three continents and against multiple variants.
The firm said the jab was 85% effective in preventing severe disease "and demonstrated complete protection against Covid-19-related hospitalisation and death as of day 28".